Pharsight

Arcapta Neohaler generic

Arcapta Neohaler is a bronchodilator owned by Novartis. It contains the active ingredient indacaterol maleate and was authorised for market use on July 1, 2011. Arcapta Neohaler is available as a powder for inhalation and holds a total of 2 drug patents.

When will Arcapta Neohaler generic be available?

The generic version of Arcapta Neohaler is expected to become available after October 11, 2028, when the last patent (US8479730) expires. The previous patent (US6878721) had expired on February 25, 2025.

Arcapta Neohaler uses

Arcapta Neohaler is a long-term, once-daily maintenance bronchodilator treatment for airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. indacaterol maleate, the active ingredient, is a beta2-adrenoceptor agonist that helps relax the muscles in the airways, improving airflow to the lungs.

Arcapta Neohaler patent expiration

Arcapta Neohaler has two patents. The first patent (US6878721) expired on February 25, 2025. The last patent (US8479730), titled 'Inhaler device,' will expire on October 11, 2028, when Arcapta Neohaler generic could become available. Below are the details of the patent:

Arcapta Neohaler dosage

Want to ask something?